UNH
Wall Street’s doing a 180
UnitedHealth woke up Thursday to a classic Wall Street glow-up: Bank of America Securities upgraded the stock from Neutral to Buy and bumped its price target from $420 to $450. Translation: one of the biggest voices on the Street just decided UNH deserves a better seat at the table.
And the market heard the message loud and clear. Shares jumped about 5% as investors piled back into managed care, a corner of healthcare that can look sleepy until suddenly it’s very much not.
Why the bulls are getting louder
BofA’s pitch is basically: the pain may be easing. The analyst pointed to improving medical cost trends and said UnitedHealth could be a leader if utilization keeps cooling off. In plain English, if patients aren’t using as many pricey services as feared, insurers get a little more breathing room.
That matters because the story around UNH has been a tug-of-war lately:
- January’s proposed Medicare Advantage rate update looked stingy and spooked investors.
- April’s final rate announcement came in much friendlier, giving managed-care stocks a shot of adrenaline.
- Now BofA thinks the setup heading into second-quarter earnings looks better than the market was giving it credit for.
The $18.25 question
UnitedHealth also raised its fiscal 2026 adjusted EPS outlook to more than $18.25, up from above $17.75 previously, versus a consensus estimate of $17.86. That’s the kind of move that makes investors perk up like they just heard the word “bonus.”
Morgan Stanley joined the party too, hiking its own price target to $453 from $395 and keeping an Overweight rating. The broader idea is that managed care could benefit from both better pricing dynamics and some AI-driven efficiency gains. If that sounds ambitious, well, welcome to healthcare in 2026: part insurance, part spreadsheet wizardry.
Big picture
UNH isn’t being treated like a defensive dinosaur right now. It’s being treated like a stock with improving fundamentals, friendlier regulation, and a Wall Street crowd that suddenly wants back in. If the medical-cost trend keeps behaving, this rally may have more room to run.